<?xml version='1.0' encoding='utf-8'?>
<document id="23784266"><sentence text="Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor."><entity charOffset="130-138" id="DDI-PubMed.23784266.s1.e0" text="edoxaban" /></sentence><sentence text="Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF)"><entity charOffset="0-8" id="DDI-PubMed.23784266.s2.e0" text="Edoxaban" /></sentence><sentence text=" P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics" /><sentence text=" Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure"><entity charOffset="1-9" id="DDI-PubMed.23784266.s4.e0" text="Edoxaban" /></sentence><sentence text="" /><sentence text="To assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors"><entity charOffset="56-64" id="DDI-PubMed.23784266.s6.e0" text="edoxaban" /></sentence><sentence text="" /><sentence text="Drug-drug interaction studies with edoxaban and CV drugs with known P-gp substrate/inhibitor potential were conducted in healthy subjects"><entity charOffset="35-43" id="DDI-PubMed.23784266.s8.e0" text="edoxaban" /></sentence><sentence text=" In 4 crossover, 2-period, 2-treatment studies, subjects received edoxaban 60 mg alone and coadministered with quinidine 300 mg (n = 42), verapamil 240 mg (n = 34), atorvastatin 80 mg (n = 32), or dronedarone 400 mg (n = 34)"><entity charOffset="66-74" id="DDI-PubMed.23784266.s9.e0" text="edoxaban" /><entity charOffset="111-120" id="DDI-PubMed.23784266.s9.e1" text="quinidine" /><entity charOffset="138-147" id="DDI-PubMed.23784266.s9.e2" text="verapamil" /><entity charOffset="197-208" id="DDI-PubMed.23784266.s9.e3" text="dronedarone" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e0" e2="DDI-PubMed.23784266.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e0" e2="DDI-PubMed.23784266.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e0" e2="DDI-PubMed.23784266.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e0" e2="DDI-PubMed.23784266.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e1" e2="DDI-PubMed.23784266.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e1" e2="DDI-PubMed.23784266.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e1" e2="DDI-PubMed.23784266.s9.e3" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e2" e2="DDI-PubMed.23784266.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s9.e2" e2="DDI-PubMed.23784266.s9.e3" /></sentence><sentence text=" Additionally, edoxaban 60 mg alone and coadministered with amiodarone 400 mg (n = 30) or digoxin 0"><entity charOffset="15-23" id="DDI-PubMed.23784266.s10.e0" text="edoxaban" /><entity charOffset="60-70" id="DDI-PubMed.23784266.s10.e1" text="amiodarone" /><entity charOffset="90-97" id="DDI-PubMed.23784266.s10.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23784266.s10.e0" e2="DDI-PubMed.23784266.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s10.e0" e2="DDI-PubMed.23784266.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s10.e0" e2="DDI-PubMed.23784266.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s10.e1" e2="DDI-PubMed.23784266.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s10.e1" e2="DDI-PubMed.23784266.s10.e2" /></sentence><sentence text="25 mg (n = 48) was evaluated in a single-sequence study and 2-cohort study, respectively" /><sentence text="" /><sentence text="Edoxaban exposure measured as area under the curve increased for concomitant administration of edoxaban with quinidine (76"><entity charOffset="0-8" id="DDI-PubMed.23784266.s13.e0" text="Edoxaban" /><entity charOffset="95-103" id="DDI-PubMed.23784266.s13.e1" text="edoxaban" /><entity charOffset="109-118" id="DDI-PubMed.23784266.s13.e2" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.23784266.s13.e0" e2="DDI-PubMed.23784266.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s13.e0" e2="DDI-PubMed.23784266.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s13.e0" e2="DDI-PubMed.23784266.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s13.e1" e2="DDI-PubMed.23784266.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s13.e1" e2="DDI-PubMed.23784266.s13.e2" /></sentence><sentence text="7 %), verapamil (52"><entity charOffset="6-15" id="DDI-PubMed.23784266.s14.e0" text="verapamil" /></sentence><sentence text="7 %), amiodarone (39"><entity charOffset="6-16" id="DDI-PubMed.23784266.s15.e0" text="amiodarone" /></sentence><sentence text="8 %), and dronedarone (84"><entity charOffset="10-21" id="DDI-PubMed.23784266.s16.e0" text="dronedarone" /></sentence><sentence text="5 %), and exposure measured as 24-h concentrations for quinidine (11"><entity charOffset="55-64" id="DDI-PubMed.23784266.s17.e0" text="quinidine" /></sentence><sentence text="8 %), verapamil (29"><entity charOffset="6-15" id="DDI-PubMed.23784266.s18.e0" text="verapamil" /></sentence><sentence text="1 %), and dronedarone (157"><entity charOffset="10-21" id="DDI-PubMed.23784266.s19.e0" text="dronedarone" /></sentence><sentence text="6 %) also increased" /><sentence text=" Administration of edoxaban with amiodarone decreased the 24-h concentration for edoxaban by 25"><entity charOffset="19-27" id="DDI-PubMed.23784266.s21.e0" text="edoxaban" /><entity charOffset="33-43" id="DDI-PubMed.23784266.s21.e1" text="amiodarone" /><entity charOffset="81-89" id="DDI-PubMed.23784266.s21.e2" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.23784266.s21.e0" e2="DDI-PubMed.23784266.s21.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s21.e0" e2="DDI-PubMed.23784266.s21.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s21.e0" e2="DDI-PubMed.23784266.s21.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s21.e1" e2="DDI-PubMed.23784266.s21.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s21.e1" e2="DDI-PubMed.23784266.s21.e2" /></sentence><sentence text="7 %" /><sentence text=" Concomitant administration with digoxin or atorvastatin had minimal effects on edoxaban exposure"><entity charOffset="33-40" id="DDI-PubMed.23784266.s23.e0" text="digoxin" /><entity charOffset="44-56" id="DDI-PubMed.23784266.s23.e1" text="atorvastatin" /><entity charOffset="80-88" id="DDI-PubMed.23784266.s23.e2" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.23784266.s23.e0" e2="DDI-PubMed.23784266.s23.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s23.e0" e2="DDI-PubMed.23784266.s23.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s23.e0" e2="DDI-PubMed.23784266.s23.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s23.e1" e2="DDI-PubMed.23784266.s23.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s23.e1" e2="DDI-PubMed.23784266.s23.e2" /></sentence><sentence text="" /><sentence text="Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure"><entity charOffset="40-49" id="DDI-PubMed.23784266.s25.e0" text="quinidine" /><entity charOffset="51-60" id="DDI-PubMed.23784266.s25.e1" text="verapamil" /><entity charOffset="66-77" id="DDI-PubMed.23784266.s25.e2" text="dronedarone" /><entity charOffset="88-96" id="DDI-PubMed.23784266.s25.e3" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e0" e2="DDI-PubMed.23784266.s25.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e0" e2="DDI-PubMed.23784266.s25.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e0" e2="DDI-PubMed.23784266.s25.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e0" e2="DDI-PubMed.23784266.s25.e3" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e1" e2="DDI-PubMed.23784266.s25.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e1" e2="DDI-PubMed.23784266.s25.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e1" e2="DDI-PubMed.23784266.s25.e3" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e2" e2="DDI-PubMed.23784266.s25.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s25.e2" e2="DDI-PubMed.23784266.s25.e3" /></sentence><sentence text=" Modest/minimal effects were observed for amiodarone, atorvastatin, and digoxin"><entity charOffset="42-52" id="DDI-PubMed.23784266.s26.e0" text="amiodarone" /><entity charOffset="54-66" id="DDI-PubMed.23784266.s26.e1" text="atorvastatin" /><entity charOffset="72-79" id="DDI-PubMed.23784266.s26.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.23784266.s26.e0" e2="DDI-PubMed.23784266.s26.e0" /><pair ddi="false" e1="DDI-PubMed.23784266.s26.e0" e2="DDI-PubMed.23784266.s26.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s26.e0" e2="DDI-PubMed.23784266.s26.e2" /><pair ddi="false" e1="DDI-PubMed.23784266.s26.e1" e2="DDI-PubMed.23784266.s26.e1" /><pair ddi="false" e1="DDI-PubMed.23784266.s26.e1" e2="DDI-PubMed.23784266.s26.e2" /></sentence><sentence text="" /></document>